Cargando…
Model‐based dose selection to inform translational clinical oncology development of WNT974, a first‐in‐class Porcupine inhibitor
WNT974 is a potent, selective, and orally bioavailable first‐in‐class inhibitor of Porcupine, a membrane‐bound O‐acyltransferase required for Wnt secretion, currently under clinical development in oncology. A phase I clinical trial is being conducted in patients with advanced solid tumors. During th...
Autores principales: | Ji, Yan, Huang, Pai‐Hsi, Woolfenden, Steve, Myers, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283749/ https://www.ncbi.nlm.nih.gov/pubmed/35620969 http://dx.doi.org/10.1111/cts.13287 |
Ejemplares similares
-
Porcupine Inhibitor LGK974 Downregulates the Wnt Signaling Pathway and Inhibits Clear Cell Renal Cell Carcinoma
por: Li, Jianyi, et al.
Publicado: (2020) -
Porcupine inhibitor LGK-974 inhibits Wnt/β-catenin signaling and modifies tumor-associated macrophages resulting in inhibition of the malignant behaviors of non-small cell lung cancer cells
por: Tang, Yang, et al.
Publicado: (2021) -
LPS-induced inflammatory response is suppressed by Wnt inhibitors, Dickkopf-1 and LGK974
por: Jang, Jaewoong, et al.
Publicado: (2017) -
Precise Regulation of Porcupine Activity Is Required for Physiological Wnt Signaling
por: Proffitt, Kyle D., et al.
Publicado: (2012) -
Morphological neurite changes induced by porcupine inhibition are rescued by Wnt ligands
por: Godoy, Juan A., et al.
Publicado: (2021)